Evaluation of Intrahepatic I-131 Ethiodol on a Patient with Hepatocellular Carcinoma

Park, Chan H.; Suh, Jung Ho; Yoo, Hyung Sik; Lee, J T; Kim, D I

doi:10.1097/00003072-198607000-00015

Cited by 37 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Lipiodol contains sterile iodine 127, so the labelling of lipiodol with radioactive I-131 can be achieved through a simple radioisotopic exchange method. 29 The therapeutic effectiveness is primarily limited to areas in which lipiodol accumulates, as I-131 generates 606-MeV b-rays that produce strong effects over distances of less than 2.0 mm. 30 These findings indicate that I-131-Lip has potential advantages for use in hepatoma therapy.…”

Section: Discussionmentioning

confidence: 99%

Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy

et al. 2005

View full text Add to dashboard Cite

“…166 Ho, 90 Y, 131 I, and 188 Re are β-emitters that have been tested for TAE [8][9][10][11][12]. Among these, 131 I-labeled lipiodol is commercially available to treat liver cancer [12][13][14][15][16]; however, drawbacks such as high-energy γ emission, long half-life, and high cost limit lipiodol's clinical application.…”

Section: Introductionmentioning

confidence: 99%

“…m, 4H, CH 2 S) 13. C-NMR (CDCl 3 , 150 MHz): δ (in ppm) = 169.95, 41.35, 31.92, 29.69, 29.35, 23.38, 22.85, 22.68, 14.11, 11.33.…”

mentioning

confidence: 99%

Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol

Banka¹,

Moon²,

Jeong³

et al. 2015

Nuclear Medicine and Biology

View full text Add to dashboard Cite

“…Lipiodol ® (Guerbet, Villepinte, France) is a clinically available embolic agent for hepatoma treatment, and its use as a carrier for chemotherapeutic agents or radioisotopes is currently under investigation. 15,16 Previously, it was shown that a 1:1 mixture of PEG-PLGA-PEG and Lipiodol could yield a stable thermogelling system for use in arterial embolization and sustained drug release. The PEG-PLGA-PEG solution had a small particle size (in the nanoscopic scale range) at low temperatures, but became larger with increasing temperature as described elsewhere.…”

mentioning

confidence: 99%

“…Radionuclides have been conjugated with monoclonal antibodies, iodized oils, and chemical compounds for the treatment of residual or unresectable HCC. 15,[21][22][23][24] Rhenium-188 ( 188 Re), a γ-and β-emitter, is an emerging and promising radionuclide for clinical use in many settings. Because…”

mentioning

confidence: 99%

Preparation and therapeutic evaluation of 188Re-thermogelling emulsion in rat model of hepatocellular carcinoma

Shih¹,

Lin²,

Yeh³

et al. 2014

IJN

View full text Add to dashboard Cite

Radiolabeled Lipiodol ® (Guerbet, Villepinte, France) is routinely used in hepatoma therapy. The temperature-sensitive hydrogel polyethylene glycol-b-poly-DL-lactic acid-co-glycolic acid-b-polyethylene glycol triblock copolymer is used as an embolic agent and sustained drug release system. This study attempted to combine the polyethylene glycol-b-poly-DL-lactic acid-co-glycolic acid-b-polyethylene glycol hydrogel and radio-labeled Lipiodol to form a new radio-thermogelling emulsion, rhenium-188–N,N’-1,2-ethanediylbis-L-cysteine diethyl-ester dihydrochloride–Lipiodol/hydrogel ( 188 Re-ELH). The therapeutic potential of 188 Re-ELH was evaluated in a rodent hepatoma model. Rhenium-188 chelated with N,N’-1,2-ethanediylbis-L-cysteine diethyl-ester dihydrochloride was extracted with Lipiodol to obtain rhenium-188–N,N’-1,2-ethanediylbis-L-cysteine diethyl-ester dihydrochloride–Lipiodol ( 188 Re-EL), which was blended with the hydrogel in equal volumes to develop 188 Re-ELH. The 188 Re-ELH phase stability was evaluated at different temperatures. Biodistribution patterns and micro-single-photon emission computed tomography/computed tomography images in Sprague Dawley rats implanted with the rat hepatoma cell line N1-S1 were observed after in situ tumoral injection of ~3.7 MBq 188 Re-ELH. The therapeutic potential of 188 Re-EL (48.58±3.86 MBq/0.1 mL, n=12) was evaluated in a 2-month survival study using the same animal model. The therapeutic effects of 188 Re-ELH (25.52±4.64 MBq/0.1 mL, n=12) were evaluated and compared with those of 188 Re-EL. The responses were assessed by changes in tumor size and survival rates. The 188 Re-ELH emulsion was stable in the gel form at 25°C–35°C for >52 hours. Biodistribution data and micro-single-photon emission computed tomography/computed tomography images of the 188 Re-ELH group indicated that most activity was selectively observed in hepatomas. Long-term 188 Re-ELH studies have demonstrated protracted reductions in tumor volumes and positive effects on the survival rates (75%) of N1-S1 hepatoma-bearing rats. Conversely, the 2-month survival rate was 13% in the control sham group. Therapeutic responses differed significantly between the two groups ( P <0.005). Thus, the hydrogel enhanced the injection stability of 188 Re-EL in an animal hepatoma model. Given the synergistic results, direct 188 Re-ELH intratumoral injection is a potential therapeutic alternative for hepatoma treatment.

show abstract

Evaluation of Intrahepatic I-131 Ethiodol on a Patient with Hepatocellular Carcinoma

Cited by 37 publications

References 0 publications

Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy

Eradication of hepatocellular carcinoma xenografts by radiolabelled, lipiodol-inducible gene therapy

Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol

Preparation and therapeutic evaluation of 188Re-thermogelling emulsion in rat model of hepatocellular carcinoma

Contact Info

Product

Resources

About